NCT05790096View on ClinicalTrials.gov

Effectiveness and Safety Study of Filgrastine® in Patientes With Breast Cancer Treated With Myelotoxic Chemotherapy

PHASE3UnknownINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

May 31, 2023

Primary Completion Date

June 30, 2024

Study Completion Date

December 31, 2024

Conditions
Breast Cancer
Interventions
BIOLOGICAL

Granulokine

Granulokine is presented in boxes containing vials containing 1,0 mL of solution for injection and 300µg of filgrastim.

BIOLOGICAL

Filgrastine

Filgrastine is presented in boxes containing vials containing 1,0 mL of solution for injection and 300µg of filgrastim.

Sponsors
All Listed Sponsors
lead

Blau Farmaceutica S.A.

INDUSTRY